Clinical experience with Cerebrolysin®

  • William Molloy
  • T. I. Standish
Conference paper


Cerebrolysin® is a peptidergic drug which displays neurotrophic action in various animal models. It is used for the treatment of dementia and in this report we provide evidence for the long-term clinical efficacy of Cerebrolysin® in Alzheimer’s disease. This evidence is based on our clinical experience with Cerebrolysin®, stemming from our participation in a double- blind, placebo-controlled clinical trial, a compassionate use programme initiated thereafter, and a PET study. Our data suggests, that Cerebrolysin® is a safe and effective treatment for Alzheimer’s disease and that repeat treatments may maintain function in patients over the long-term.


Nerve Growth Factor MMSE Score Growth Factor Peptide Nootropic Drug Septal Cholinergic Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akai F, Hiruma S, Sato T, Iwamoto N, Fujimoto M, Ioku M, Hashimoto S (1992) Neurotrophic factor like effect of FPF1070 on septal cholinergic neurons after transection of fimbria-fornix in the rat brain. Histol Histopathol 7: 213 – 221PubMedGoogle Scholar
  2. Francis-Turner L, Valouskova V (1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transsection: Short-term study. Neurosci Lett 202: 193 – 196PubMedCrossRefGoogle Scholar
  3. Hefti FL, Schneider S (1991) Nerve growth factor and Alzheimer’s disease. Clin Neuropharmacol 14: 62 – 76CrossRefGoogle Scholar
  4. Olson L, Nordberg A, von Hoist H, Backman L, Ebendal T, Alafuzoff I, Amberla K, Hartvig P, Herlitz A, Lilja A, et al (1992) Nerve growth factor affects HC-nicotine binding, blood flow, EEG and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect 4 (1): 79 – 95PubMedGoogle Scholar
  5. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, et al (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 50: 136 – 145PubMedGoogle Scholar
  6. Ruther W, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 27: 32 – 40PubMedCrossRefGoogle Scholar
  7. Tuszynski MH, Gage FH (1990) Potential use of neurotrophic agents in the treatment of neurodegenerative disorders. Acta Neurobiol Exp 50: 323 – 332Google Scholar
  8. Windisch M, Albrecht E, Eggenreich U, Paier B (1993) Neurotrophic effects of the nootropic drug Cerebrolysin — A summary. In: Nicolini M, Zatta PF, Corain B (eds) Advances in the biosciences, vol. 87, Pergamon Press, Oxford, 355 – 357Google Scholar
  9. Windisch M, Piswanger A (1987) EinfluB einer 7tagigen Behandlung mit Cerebrolysin auf die Atmung von Hirnmitochondrien. Neuropsychiatrie 1 (2): 83 – 88Google Scholar

Copyright information

© Springer-Verlag/Wien 2000

Authors and Affiliations

  • William Molloy
    • 1
  • T. I. Standish
    • 2
  1. 1.Geriatric Research GroupMcMaster University Department of MedicineHamiltonCanada
  2. 2.Geriatric Clinics, Ground Floor, 40 WingHenderson HospitalHamilton (Ontario)Canada

Personalised recommendations